Interface Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 25 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.95 M
- Satisfied Charges ₹ 1.55 M
- Revenue Growth 57.91%
- Profit Growth 98.90%
- Ebitda 79.08%
- Net Worth 53.51%
- Total Assets 43.08%
About Interface Pharmaceuticals
Interface Pharmaceuticals Pvt Ltd (IPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 June 1999 and has a history of 25 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹7.95 M. The company has closed loans amounting to ₹1.55 M, as per Ministry of Corporate Affairs (MCA) records.
Sudhir Malhotra, Promila Malhotra, Manan Malhotra, and One other member serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232DL1999PTC100229
- Company No.
100229
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Interface Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Promila Malhotra  | Director | 14-Jun-1999 | Current |
| Sudhir Malhotra | Director | 14-Jun-1999 | Current |
| Manan Malhotra | Director | 25-Jul-2022 | Current |
| Shilpa Malhotra | Director | 20-Oct-2019 | Current |
Financial Performance of Interface Pharmaceuticals.
Interface Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 57.91% increase. The company also saw a substantial improvement in profitability, with a 98.9% increase in profit. The company's net worth Soared by an impressive increase of 53.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Interface Pharmaceuticals?
In 2022, Interface Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.95 M
₹1.55 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Sep 2023 | Hdfc Bank Limited | ₹7.95 M | Open |
| 22 Nov 2008 | The Nainital Bank Limited | ₹0.90 M | Satisfied |
| 20 Sep 2004 | The Nainital Bank | ₹0.65 M | Satisfied |
How Many Employees Work at Interface Pharmaceuticals?
Unlock and access historical data on people associated with Interface Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Interface Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Interface Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.